Department of Oncotherapy - Szeged

6720 Szeged, Korányi fasor 12.
Tel: 62/545404 Fax: 62/545922
Email: Show contact form

Director: Prof. Dr. Judit Oláh, DSc

2013.

  1. Jassem J, Ozmen V, Bacanu F, Drobniene M, Eglitis J, Lakshmaiah KC, Kahan Z, Mardiak J, Pienkowski T, Semiglazova T, Stamatovic L, Timcheva C, Vasovic S, Vrbanec D, Zaborek P.
    Delays in diagnosis and treatment of breast cancer: a multinational analysis.
    Eur J Public Health. 2013 Sep 12.
  2. Vrdoljak E, Rini B, Schmidinger M, Omrčen T, Torday L, Szczylik C, Sella A.
    Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
    Anticancer Drugs. 2013 5:431-40.
  3. Maráz A, Bodrogi I, Csejtei A, Dank M, Géczi L, Küronya Z, Mangel L, Petrányi A, Szûcs M, Bodoky G.
    First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer.
    Magy Onkol. 2013 3:173-6.
  4. Maráz A, Furák J, Varga Z, Fodor E, Együd Z, Borzási E, Kahán Z, Pálföldi R, Tiszlavicz L, Hideghéty K.
    Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer.
    Anticancer Res. 2013 4:1737-41.
  5. Maráz A, Furák J, Varga Z, Kahán Z, Tiszlavicz L, Hideghéty K.
    Thrombocytosis has a negative prognostic value in lung cancer.
    Anticancer Res. 2013 4:1725-9.
  6. Daróczi B, Szántó E, Tóth J, Barzó P, Bognár L, Bakó G, Szántó J, Mózes P, Hideghéty K.
    Post-operative management of primary glioblastoma multiforme in patients over 60 years of age.
    Ideggyogy Sz. 2013 11-12:391-8.
  7. Mozes P, Szanto E, Tiszlavicz L, Barzo P, Cserhati A, Fodor E, Hideghety K.
    Clinical Course of Central Neurocytoma with Malignant Transformation-An Indication for Craniospinal Irradiation.
    Pathol Oncol Res. 2013 Oct 12.
  8. Hideghéty K, Plangár I, Mán I, Fekete G, Nagy Z, Volford G, Tőkés T, Szabó E, Szabó Z, Brinyiczki K, Mózes P, Németh I.
    Development of a small-animal focal brain irradiation model to study radiation injury and radiation-injury modifiers.
    Int J Radiat Biol. 2013 8:645-55.
  9. Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C; Central European Cooperative Oncology Group.
    Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
    Lancet Oncol. 2013 2:125-33.
  10. Rusz O, Kahán Z.
    Bone homeostasis and breast cancer: implications for complex therapy and the maintenance of bone integrity.
    Pathol Oncol Res. 2013 1:1-10.
  11. Takács T, Paszt A, Simonka Z, Abrahám S, Borda B, Ottlakán A, Ormándi K, Lázár M, Vörös A, Kahán Z, Lazar G.
    Radioguided occult lesion localisation versus wire-guided lumpectomy in the treatment of non-palpable breast lesions.
    Pathol Oncol Res. 2013 2:267-73.
  12. Vörös A, Csörgő E, Kővári B, Lázár P, Kelemen G, Cserni G.
    The Use of Digital Images Improves Reproducibility of the Ki-67 Labeling Index as a Proliferation Marker in Breast Cancer.
    Pathol Oncol Res. 2013 Nov 8.

Division "A":

H-6720 Szeged,
Korányi fasor 12.
Phone: +36 62 545404
Fax: +36 62 545922
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Office hours: 9-13 h
Informations: +36 62 544960

Division of Infusion Chemotherapy

6720 Szeged, Korányi fasor 7.
Office hours: 9-13 h
Informations: 62/342627, 62/342628

Division of Hódmezővásárhely

H-6800 Hódmezõvásárhely
Dr. Imre József u. 2.
Office hours: 9-10 h
Informations: 62/532-297